Researchers have identified KARAP (killer cell activating receptor-associated protein), the protein product of the TYROBP gene, as a macrophage-centered regulator that may shape ulcerative colitis (UC ...

Palisade Bio's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. I rate PALI stock as Buy.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not ...

eBay stock is hovering near an entry after getting a strong response to its Q3 results, adding to a recent rally.

InnoCare Pharma announced that the first subject has been dosed in the Phase 1 trial of ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the potential treatment of autoimmune diseases, ...

10/13/2026 04:44 PM ET Alissa Coram and Ken Shreve walk through Tuesday's market action with a discussion of key stocks to watch in Stock ...

Rituximab has been linked to a higher risk of inflammatory bowel disease than other MS therapies. Explore what it means for ...

Texas Instruments is the IBD Stock Of The Day as the analog chipmaker passes an early buy point following earnings.

A major study has uncovered hidden warning signs of inflammatory bowel disease in the blood up to 10 years before diagnosis.

Spyre Therapeutics has seen its share price move sharply in recent years, so the question now is whether a US$90.33 stock is ...

Looking for the best green investments? IBD's 50 Most Sustainable Companies combine high sustainability scores and superior stock ratings.